• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Dyadic International Inc.

    3/6/26 5:04:30 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    false 0001213809 0001213809 2026-03-06 2026-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 6, 2026

     

     

    Dyadic International, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-32513   45-0486747

    (State or other jurisdiction

    of incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    1044 North U.S. Highway One, Suite 201

    Jupiter, FL 33477

    (Address of principal executive offices and zip code)

     

    (561) 743-8333

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   DYAI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On March 6, 2026, Dyadic International, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time, at its option, shares of the Company’s common stock having an aggregate offering price of up to $4,237,818 from time to time through the Sales Agent. The issuance and sale, if any, of shares of the Company’s common stock under the Sales Agreement will be made pursuant to the Company’s registration statement on Form S-3 (File No. 333-273829), which became effective on August 25, 2023, and the related prospectus supplement dated March 6, 2026 (the “Prospectus Supplement”), in each case filed with the U.S. Securities and Exchange Commission (the “SEC”).

     

    The sale, if any, of shares of the Company’s common stock under the Sales Agreement will be made by any method permitted that is deemed to be an “at-the-market” equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including block trades and sales made in ordinary brokers’ transactions directly on The Nasdaq Capital Market or any other trading market for the Company’s common stock at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Subject to the terms and conditions of the Sales Agreement, the Sales Agent will use their commercially reasonable efforts to sell the shares of the Company’s common stock from time to time, based upon the Company’s instructions. The Company is not obligated to sell any shares of common stock under the Sales Agreement. The Company or the Agent may at any time suspend or terminate the offering of the ATM Shares upon notice to the other party and subject to other conditions.

     

    The compensation payable to the Sales Agent as sales agent shall be up to 3.0% of the gross sales price of the shares sold through the sales agent pursuant to the Sales Agreement. In addition, the Company will reimburse the Sales Agent for certain expenses incurred in connection with the Sales Agreement, and the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Sales Agent against certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended.

     

    The Sales Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the material terms of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the exhibit attached hereto.

     

    The representations, warranties and covenants contained in the Sales Agreement were made solely for the benefit of the parties to the Sales Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Sales Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Sales Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.

     

    A copy of the legal opinion of White & Case LLP relating to the shares of common stock being offered pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock discussed herein, nor shall there be any offer, solicitation, or sale of the shares of common stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.   Description
       
    1.1†   At-The-Market Issuance Sales Agreement, by and between Dyadic International, Inc. and Craig-Hallum Capital Group LLC, dated March 6, 2026.
       
    5.1   Opinion of White & Case LLP.
       
    23.1   Consent of White & Case LLP (contained in Exhibit 5.1).
       
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    † Certain of the schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted schedules to the SEC upon its request. 

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 6, 2026 Dyadic International, Inc.
           
        By: /s/ Mark A. Emalfarb
        Name: Mark A. Emalfarb
        Title: Chief Executive Officer


     

     

    Get the next $DYAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    10/23/2025$3.00Buy
    H.C. Wainwright
    9/8/2025Buy
    Craig Hallum
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

    JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio ("Fermbox"), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). This represents the first commercialized product under the companies expanded collaboration announced

    3/4/26 7:20:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

    JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS ("Inzymes"), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion

    3/2/26 7:20:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

    JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals ("Proliant"), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic's proprietary filamentous fungal expression technology. The launch of AlbuFree™ DX undersco

    2/17/26 7:25:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    SEC Filings

    View All

    SEC Form 8-K filed by Dyadic International Inc.

    8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/6/26 5:04:30 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Dyadic International Inc.

    424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/6/26 5:02:34 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dyadic International Inc.

    SCHEDULE 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/17/26 4:14:24 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP of Research and Bus. Dvlpmt Tchelet Ronen was granted 18,064 shares, increasing direct ownership by 55% to 50,897 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:12:29 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Rawson Ping Wang was granted 29,158 shares, increasing direct ownership by 21% to 170,151 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:11:42 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucy Patrick K. converted options into 21,552 shares, increasing direct ownership by 42% to 72,311 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:10:38 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Hazelton Joseph P bought $24,700 worth of shares (26,000 units at $0.95), increasing direct ownership by 20% to 155,340 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    8/5/25 5:00:10 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Dyadic International

    Craig Hallum initiated coverage of Dyadic International with a rating of Buy

    9/8/25 8:52:07 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic International downgraded by Dawson James

    Dawson James downgraded Dyadic International from Buy to Neutral

    7/18/22 9:59:51 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Financials

    Live finance-specific insights

    View All

    Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

    JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, November 12, 2025. Conference Call Information Date: Wednesday, November 12, 2025 Time: 5:00 p.m. Eastern Tim

    10/29/25 7:25:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

    JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-

    8/5/25 4:11:35 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

    Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

    5/14/25 4:05:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    View All

    Dyadic Appoints Doug Pace to Its Executive Leadership Team

    JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

    10/9/23 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Appoints Chief Business Officer to Executive Leadership Team

    JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

    11/9/21 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/13/24 4:41:59 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/1/24 4:15:18 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    3/14/23 4:01:06 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care